BioSig Technologies, Inc.
  • Home
  • About BioSig
    • About BioSig
    • Overview
    • Partnerships
  • Our Technology
    • Our Technology
    • The PURE EP Platform
      • Overview
      • ATC
      • NFT
    • Publications
  • News & Media
    • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Events
  • Investors
    • Investors
    • Overview
    • News / Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Information
      • Profile
      • Leadership Team
      • Contacts
      • FAQ
    • Financial Information
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Financial Results
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Governance Documents
  • Contact
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Profile
    • Leadership Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed

Press Releases

  • News / Events

  • Press Releases
  • IR Calendar
  • Email Alerts

BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

September 15, 2020

BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

September 14, 2020

Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

September 14, 2020

ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

September 9, 2020

BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

September 2, 2020

BioSig Technologies to Present at The LD 500 Virtual Conference

August 25, 2020

Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board

August 6, 2020

ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board

August 5, 2020

BioSig Installs PURE EP(tm) System at Massachusetts General Hospital

August 4, 2020

BioSig Awarded CAGE Code by the Systems for Award Management (SAM)

August 3, 2020
rss_feed News RSS
  • Previous
    • 1...
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • ...37
    Next
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    x formerly known as twitter icon X formerly known as Twitter
    linkedin Facebook
    © 2025 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap